Sigma, which is still finalising its full-year accounts for the year ended January 31, 2010, said in a market update on Thursday that increased recent market pressures, especially in its generic drugs business, had led to a fall in cash flow forecast. The reduction in the expected cash flows,

THERE has to be more going on, and going wrong, at Sigma Pharmaceuticals than yesterday's update reveals. After three weeks suspended from trade to grapple with earnings guidance for the year to January 2010, the company has clarified that looming balance sheet write-downs are the major

INVESTORS in drug maker and pharmacy group Sigma Pharmaceuticals will learn on Tuesday the extent of the company's financial woes, but the company warned them yesterday not to expect a second-half dividend. As accountants, auditors and the board pored over the company's

Sigma, which is still finalising its full year accounts for the year ended January 31, 2010, said in a market update on Thursday that increased recent market pressures , especially in its generic drugs business, had led to a fall in cash flow forecast. The reduction in the expected cash